vs
Side-by-side financial comparison of Boston Scientific (BSX) and Gold.com, Inc. (GOLD). Click either name above to swap in a different company.
Gold.com, Inc. is the larger business by last-quarter revenue ($10.4B vs $5.2B, roughly 2.0× Boston Scientific). Boston Scientific runs the higher net margin — 25.7% vs 0.6%, a 25.2% gap on every dollar of revenue. On growth, Gold.com, Inc. posted the faster year-over-year revenue change (244.0% vs 11.6%). Over the past eight quarters, Gold.com, Inc.'s revenue compounded faster (95.3% CAGR vs 12.4%).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Kinross Gold Corporation is a Canadian-based gold and silver mining company founded in 1993 and headquartered in Toronto, Ontario, Canada. Kinross currently operates six active gold mines, and was ranked fifth of the "10 Top Gold-mining Companies" of 2019 by InvestingNews. The company's mines are located in Brazil, Mauritania, and the United States. It trades under the KGC ticker in the New York Stock Exchange, and under K in the Toronto Stock Exchange.
BSX vs GOLD — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $10.4B |
| Net Profit | $1.3B | $59.5M |
| Gross Margin | 69.5% | 1.7% |
| Operating Margin | — | — |
| Net Margin | 25.7% | 0.6% |
| Revenue YoY | 11.6% | 244.0% |
| Net Profit YoY | — | 411.2% |
| EPS (diluted) | $0.90 | $2.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 26 | — | $10.4B | ||
| Q2 26 | — | $6.5B | ||
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $148.1M | ||
| Q3 25 | $5.1B | $3.7B | ||
| Q2 25 | $5.1B | $2.5B | ||
| Q1 25 | $4.7B | $3.0B | ||
| Q4 24 | $4.6B | $2.7B |
| Q3 26 | — | $59.5M | ||
| Q2 26 | — | $11.6M | ||
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $11.6M | ||
| Q3 25 | $755.0M | $-939.0K | ||
| Q2 25 | $795.0M | $10.3M | ||
| Q1 25 | $672.0M | $-8.5M | ||
| Q4 24 | $563.0M | $6.6M |
| Q3 26 | — | 1.7% | ||
| Q2 26 | — | 1.4% | ||
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | 63.0% | ||
| Q3 25 | 69.9% | 2.0% | ||
| Q2 25 | 67.7% | 3.3% | ||
| Q1 25 | 68.8% | 1.4% | ||
| Q4 24 | 67.8% | 1.6% |
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 10.7% | ||
| Q3 25 | 20.7% | -0.0% | ||
| Q2 25 | 16.2% | 0.5% | ||
| Q1 25 | 19.8% | -0.3% | ||
| Q4 24 | 14.8% | 0.3% |
| Q3 26 | — | 0.6% | ||
| Q2 26 | — | 0.2% | ||
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | 7.9% | ||
| Q3 25 | 14.9% | -0.0% | ||
| Q2 25 | 15.7% | 0.4% | ||
| Q1 25 | 14.4% | -0.3% | ||
| Q4 24 | 12.3% | 0.2% |
| Q3 26 | — | $2.09 | ||
| Q2 26 | — | $0.46 | ||
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $0.46 | ||
| Q3 25 | $0.51 | $-0.04 | ||
| Q2 25 | $0.53 | $0.43 | ||
| Q1 25 | $0.45 | $-0.36 | ||
| Q4 24 | $0.38 | $0.27 |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $153.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 2.57× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 26 | — | $153.0M | ||
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $-42.6M | ||
| Q3 25 | $1.3B | $195.4M | ||
| Q2 25 | $1.3B | $67.0M | ||
| Q1 25 | $541.0M | $102.8M | ||
| Q4 24 | $1.5B | $110.1M |
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $-46.6M | ||
| Q3 25 | $1.2B | $193.4M | ||
| Q2 25 | $1.1B | $63.1M | ||
| Q1 25 | $354.0M | $100.4M | ||
| Q4 24 | $1.2B | $106.4M |
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | -31.5% | ||
| Q3 25 | 22.9% | 5.3% | ||
| Q2 25 | 22.3% | 2.5% | ||
| Q1 25 | 7.6% | 3.3% | ||
| Q4 24 | 25.8% | 3.9% |
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 2.7% | ||
| Q3 25 | 3.6% | 0.1% | ||
| Q2 25 | 3.1% | 0.2% | ||
| Q1 25 | 4.0% | 0.1% | ||
| Q4 24 | 6.1% | 0.1% |
| Q3 26 | — | 2.57× | ||
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | -3.66× | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.62× | 6.49× | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 2.59× | 16.78× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| Cardiovascular | $3.5B | 67% |
| Endoscopy | $736.0M | 14% |
| Urology | $646.0M | 12% |
| Neuromodulation | $318.0M | 6% |
GOLD
Segment breakdown not available.
